Neurizon Therapeutics Limited (ASX:NUZ)

Australia · Delayed Price · Currency is AUD

0.0730

+0.0010 (1.39%)

Jul 7, 2026, 2:19 PM AEST

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Corporate & Research	1.54M	841.71K	950.39K	834.70K	606.61K
Corporate & Research Growth	82.70%	-11.43%	13.86%	37.60%	-24.89%
Pharmaceutical - Epichem	-	-	3.11M	3.76M	3.14M
Pharmaceutical - Epichem Growth	-	-	-17.15%	19.82%	-9.08%
Inter-Segment Elimination	-	-	-163.51K	-82.03K	-71.31K
Total	1.54M	841.71K	3.90M	4.51M	3.67M
Total Growth	82.70%	-78.42%	-13.53%	22.85%	-10.96%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Switzerland	17.28K	1.04M	1.13M
Switzerland Growth	-98.34%	-7.74%	-8.83%
Australia	2.69M	1.74M	685.01K
Australia Growth	54.75%	153.52%	-20.70%
USA	100.44K	181.70K	114.24K
USA Growth	-44.72%	59.05%	-86.88%
Others	18.76K	96.09K	210.59K
Others Growth	-80.48%	-54.37%	-4.73%
Sweden	-	323.85K	-
Total	2.82M	3.38M	2.14M
Total Growth	-16.48%	57.98%	-33.03%